Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 29, 2020

Primary Completion Date

April 5, 2020

Study Completion Date

May 25, 2020

Conditions
COVID-19FavipiravirKaletraHydroxychloroquineLopinavir/Ritonavir
Interventions
DRUG

Favipiravir

Patients will be given a stat dose of 1600mg Favipiravir tablets for the first time, and for next time they will be given 600mg of favipiravir tablets three times per day for 7 days

DRUG

Hydroxychloroquine

200mg of Hydroxychloroquine two times per day will be given to patients for seven days in Test group, and Patients in Control group will be given a stat dose of 400mg Hydroxychloroquine tablets two times per day.

DRUG

Lopinavir / Ritonavir

Patients will be given 200/50 mg of Lopinavir / Ritonavir two times per day for seven days.

Trial Locations (1)

0

Mohammad Sadegh Bagheri Baghdasht, Tehran

All Listed Sponsors
lead

Baqiyatallah Medical Sciences University

OTHER

NCT04376814 - Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19 | Biotech Hunter | Biotech Hunter